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Purpose: To formulate the extracts of the stem bark of Alstonia boonei, an important 
antimalarial herb, into tablet dosage form. 
Methods: Tablets were formulated using direct compression and wet granulation methods. 
The mechanical properties of the tablets were assessed using crushing strength and friability 
and the crushing strength:friability ratio (CSFR) while drug release properties were evaluated 
using disintegration and dissolution times.  
Results: There were statistically significant (p<0.01) differences in the CSFR values and drug 
release properties of A. boonei tablets prepared by both methods. The differences depended 
on the type and concentration of excipient and binder employed in the formulation.  
Conclusions: The method of preparation of the A. boonei tablets needs to be carefully 
selected to ensure the production of tablets with adequate bond strength to withstand the 
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INTRODUCTION 
Alstonia boonei De Wild belongs to the family 
called Apocynaceaee which consists of about 
50 species widely distributed in the continents 
of Africa, Asia and America
1-3
. Alstonia 
boonei, known as Ahun in Yoruba, Egbu-ora 
in Igbo, Ukhu in Edo and Ukpukunu in 
Urhobo, is a widely distributed plant in the 
lowlands and rain-forest areas of Nigeria. 
Parts of the plant are employed for the 
treatment of a variety of ailments in Africa and 
the stem bark has been listed in the African 
Pharmacopoeia as an anti-malarial drug. The 
stem bark of A. boonei is used in traditional 
medicine to treat fever, painful micturition, 
insomnia, chronic diarrhea, rheumatic pains, 
as anti-venom for snake bites and in the 
treatment of arrow poisoning
4-7
. The chemical 
constituents include alkaloids, triterpenoids 
and steroids
2,4
. Over 90% of the isolated 
chemical constituents are alkaloids many of 
which are the indole types
2,4
. The major 
alkaloids are echitamine and echitamidine. In 
vitro antiplasmodial activity of the alkaloids 
against both drug sensitive and resistant 
strains of P. falciparum
8 
and in vivo activity 
against P. berghei in mice
9,10
 have been 
reported. In another trial, the anti-inflammatory 
properties of the alcoholic extract A. boonei in 
rat hind paw edema has been used to justify 
its use in herbal medicine for the treatment of 




In spite of their efficacy, herbal medicinal 
products have been widely criticized due to 
lack of standardization and poor-quality 
presentation. In traditional medicine, the stem 
bark of A. boonei is usually soaked in water 
and unspecified quantities of the decoction 
are ingested. However, to improve patient 
compliance and acceptance, there is need to 





Thus, the aim of the 
present study is to produce conventional 
tablets of the extracts of the stem bark of A. 
boonei for oral administration using direct 
compression and wet granulation methods to 
determine the more suitable method for the 
preparation of the tablets. The mechanical 
properties of the tablets were assessed using 
crushing strength and friability and the 
crushing strength friability ratio (CSFR) while 
the drug release properties were assessed 
using the disintegration and dissolution times.   
 
MATERIALS AND METHODS 
The materials used were Emcompress
® 
(dicalcium phosphate, Mendell Co Ltd., 
Surrey, UK), Avicel
®
 PH 102 (FMC 
International Co. Cork, Ireland), lactose (DMV, 
Veghel, Netherlands), polyvinylpyrrolidone, 
PVP average molecular weight 360,000 
(Aldrich Chemicals Co Limited, Gillingham, 
Dorset, UK), corn starch B.P (BDH Chemicals, 
Poole, UK), magnesium stearate (Hopkin and 
Williams, Chadwell, Health, Essex, UK), and 
absolute ethanol 96% (BDH Chemicals, 
Poole, UK). 
The stem bark of Alstonia boonei was 
purchased from the herbal wholesalers at 
Oyingbo market, Lagos, Nigeria and 
authenticated at the Forestry Research 
Institute of Nigeria, Ibadan, Nigeria (Voucher 
FHI 107254). 
 
Extraction of the Powdered Stem Bark 
The stem bark was washed and then dried in 
a GallenKamp Moisture Extraction Oven 
(Model: BS 250 GallenKamp Co., UK) at 40
o
C 
for four days. The dried bark was ground to a 
coarse powder using a laboratory mill 
(Kenwood UK Ltd, Hertfordshire UK). 6 Kg of 
the powdered sample was exhaustively 
extracted three times with 10L absolute 
ethanol for 48h by maceration. The solvent 
was removed at 30°C under reduced pressure 
and then evaporated to dryness. The dried 
extract was reduced to powder using a 
laboratory mill and then sieved with a 120 µm 
mesh sieve. The yield was 6%w/w.  
 
Preparation of Powder Mixtures for Direct 
Compression 





 in a ratio 
of 1:9 and 1:4 drug: excipient were thoroughly 
mixed and stored in airtight containers. 
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Table 1: Crushing strength, friability, crushing strength-friability ratio of Alstonia boonei 
 tablets prepared by direct compression and wet granulation (mean±SD, n=4) 
 
Direct compression Compression 
Pressure 
(KN) 







      
5   55.92±1.30 0.58±0.01 96.41 
10   63.77±1.48 0.53±0.02 120.32 
5 Lactose  1:4 33.65±0.08 1.27±0.02 26.50 
10   64.06±0.01 0.87±0.03 73.63 
5  1:9 46.79±1.84 1.39±0.01 33.66 
10   62.49±0.87 1.18±0.02 52.96 
5 Avicel
® 
PH 102 1:4 178.54±1.91 0.43±0.01 415.21 
10   188.35±1.85 0.39±0.01 482.20 
5  1:9 192.28±0.99 0.44±0.01 437.00 
10   199.14±1.71 0.40±0.02 497.65 
5 Emcompress
®
 1:4 34.34±2.33 2.05±0.02 16.75 
10   47.09±2.54 1.43±0.07 32.93 
5  1:9 45.13±1.32 1.99±0.03 22.68 
10   51.99± 5.63 1.63±0.02 31.90 
 
 Wet granulation 







     
PVP 1 101.04±1.23 0.62±0.01 162.97 
  108.89±1.18 0.57±0.01 191.04 
 4 161.87±1.09 0.51±0.01 317.39 
  178.54±0.68 0.41±0.02 435.46 
Gelatin 1 94.18±0.52 0.66±0.02 142.70 
  120.66±0.55 0.53±0.01 227.66 
 4 116.74±0.63 0.60±0.02 194.57 
  172.66±0.59 0.51±0.03 338.55 
Cornstarch 1 38.26±0.50 0.87±0.02 43.98 
  47.09±0.67 0.69±0.01 68.25 
 4 81.42±0.52 0.67±0.03 121.52 
  114.78±0.59 0.55±0.02 208.69 
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Preparation of Granules  
Batches (200 g) of a basic formula of A. boonei 
extract (10 or 20% 
w
/w), lactose (70 or 80% 
w
/w) 
and corn starch (10% 
w
/w) were dry-mixed for 
five minutes in a Kenwood planetary mixer and 
then moistened with 1% 
w
/w or 4% 
w
/w 
concentration of binder solution (PVP or corn 
starch mucilage). The wet masses were 
granulated by passing them manually through 
a No. 12 mesh sieve (1,400 µm) (BS 410, 
Endecotts Ltd, London, UK), dried in hot air 
oven for 18 hours at 50
0
C, and then resieved 
through a No. 16 mesh size (1,000 µm). The 
granules were stored in airtight containers.  
The moisture contents of the powder and 
granule formulations were determined with an 
Ohaus moisture balance (Ohaus Scale 
Corporation, USA) and found to be between 




Preparation of Tablets 
Tablets (final weight - 500 mg) were prepared 
from the powder mixture and granules (500-
1000 µm size fractions) by compressing the 
materials for thirty seconds with 
predetermined loads of 5 and 10KN using a 
Carver Hydraulic Hand Press (Model C, 
Carver Inc, Menomonee Falls, WI, USA). 
Before each compression, the die (10.5 mm 
diameter) and the flat-faced punches were 
lubricated with a 2%
w
/w dispersion of 
magnesium stearate in ethanol: ether (1:1 
solution). After ejection, the tablets were 
stored over silica gel for 24 hours to allow 
hardening and elastic recovery. 
 
Crushing Strength and Friability Tests 
The load (N) required to diametrically break 
each tablet (crushing strength, CS) was 
determined at room temperature using a PTB 
301 crushing strength tester (Pharmatest, 
Switzerland). The friability (F) of the tablets 
were determined using a friabilator (Model TF 
2D, Scientific Equipment Ltd., Bombay, India) 




The disintegration times (DT) of the tablets 
were determined in distilled water at 37±0.5
0
C 
using an Erweka disintegration testing 
apparatus (Model: Copley ZT2, Erweka 
Apparatebau GMBH, Heusenstamm, 
Germany). 
 
Determination of absorption maxima for 
Alstonia boonei stems bark extract 
1g of the extract was placed in a 100ml flask 
and 50mL of 0.1M HCl was added. The flask 
was agitated in a shaker for about 1hr, and 
then filtered through a Whatman filter paper. 
The absorption spectrum of the solution of the 
extract was recorded using a UV 
spectrophotometer (Model Cintra 6, Type 
GBC UV–Visible, GBC, Scientific Equipment 
Ltd, Victoria, Australia) and the wavelength for 
maximum absorption was determined. 
Various concentrations of the ethanolic extract 
of Alstonia boonei were prepared to contain 
between 0.02 to 0.1mg/mL of extract in 0.1M 
HCl. The absorbance of each concentration 
was taken at 220nm and plotted against the 
various concentrations to obtain the 
calibration curve for the extract.    
 
Dissolution Test 
The dissolution times of the tablets were 
determined at 37±0.5
0
C in 900ml of 0.1M HCl 
using a Dissolution Test Apparatus (DA-6D, 
Veego Scientific Devices Mumbai, India) with 
the basket rotated at 50rpm. 5ml samples 
were withdrawn and replaced with fresh 
medium at fixed time intervals. The samples 
were diluted and the amount of drug released 
was determined spectrophotometrically at 




Alstonia boonei tablets were stored at a 
temperature of 30±2
o
C and relative humidity 
of 75±5% for a period of twelve (12) months. 
The mechanical and release properties of the 




Statistical analysis was carried out using 
computer software, GraphPad Prism® 4 
(GraphPad Software Inc. San Diego, USA). 
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Tukey-Kramers multiple comparison tests 
were used to compare the effects of the 
method of preparation and the 
excipient/binder on the mechanical and 
release properties of the tablets. At 95% 
confidence interval, P values less than or 
equal to 0.05 were considered significant. 
RESULTS 
The results of the mechanical properties of the 
A. boonei tablets prepared using direct 
compression and wet granulation are shown 
in Table 1. The results indicate that CS 
increased while F decreased with increase in 
the compression force. A. boonei extract was 
      Table 2: Disintegration (DT) and dissolution times (t50, t80) of Alstonia boonei tablets prepared by direct  
      compression and wet granulation (mean±SD, n=4) 
 












      
5   1.47±0.02 44.66± 0.03 66.89± 0.22 
10   2.32±0.02 46.80±0.03 72.87±0.31 
5 Lactose  1:4 0.30±0.04 0.50±0.02 0.70±0.14 
10   0.40±0.04 0.60±0.02 0.70±0.17 
5  1:9 0.43±0.04 0.80±0.03 0.90 ±0.25 





1:4 3.33±0.04 66.06±0.04 93.04± 0.22 
10   5.77±0.08 80.90±0.51 125.02±0.24 
5  1:9 59.83±0.05 97.95±0.64 168.20±0.14 
10   79.00±0.11 120.40±0.84 182.79±0.12 
5 Emcompress
®
 1:4 0.50±0.04 1.04±0.02 10.90±0.22 
10   0.63±0.04 3.13±0.04 23.90±0.17 
5  1:9 0.60±0.06 5.98±0.34 75.12±0.24 















PVP 1 1.32±0.04 14.90±0.02 76.88±0.14 
  1.60±0.04 21.00±0.03 78.79±0.23 
 4 9.83±0.02 32.00±0.04 155.75±0.24 
  10.17±0.04 15.00±0.03 162.01±0.18 
Gelatin 1 2.35±0.05 25.00±0.05 84.96±0.21 
  2.50±0.06 30.00±0.02 140.97±0.17 
 4 4.23±0.04 26.00±0.02 89.89±0.24 
  6.17±0.07 34.00±0.03 107.88±0.18 
Corn starch 1 0.58±0.02 15.00±0.04 28.97±0.14 
  0.77±0.03 15.00±6.03 32.04±0.21 
 4 0.75±0.04 12.00±0.03 14.88±20.11 
  1.07±0.05 15.00±0.04 35.87±0.21 
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compressible and formed intact tablet without 
the addition of any diluent. The ranking of 
crushing strength values for tablets prepared 
by direct compression was Avicel
®
 > lactose > 
Emcompress
®
, while the ranking was 
reversed for friability. The ranking of CS 
values for tablets prepared by wet granulation 
was PVP > gelatin > corn starch. The CSFR 
values also increased with increasing 
compression force and concentration of 
diluent/binder employed. The ranking of CSFR 
values for tablets prepared by direct 
compression was Avicel
®
 > lactose > 
Emcompress
®
, while the ranking was 
cornstarch > gelatin > PVP for tablets 
prepared by wet granulation.  
 
The drug release properties of pharmaceutical 
tablets are characterized by the disintegration 
and dissolution times. The result of the 
spectrophotometric analysis shows that the 
ethanolic extract of A. boonei exhibited a 
principal absorption maximum at 220nm 
typical for alkaloids with an indole 
chromophore
14
. Thus, the calibration curve to 
assess the release properties of the tablets 
were determined at a wavelength of 220nm 
and the linear regression equation for the plot 
of absorbance versus concentration was given 
as y = 3.7183x + 0.0007 with coefficient of 
determination, r
2
 = 0.997. The amount of drug 
released was plotted against time and 
representative plots for tablets containing the 
extract alone, Avicel
® 
as direct compression 
excipient and cornstarch as binder are 
presented in Fig. 1. The dissolution time (t50 
and t80 - time required for 50% and 80% of A. 
boonei to be released respectively) were 
obtained from the dissolution profiles of the 
tablets. The disintegration and dissolution 
times of the tablets are shown in Table 2. The 
ranking of disintegration and dissolution times 






lactose, while the ranking for tablets prepared 







The mechanical properties of pharmaceutical 
tablets are important tests for pharmaceutical 
tablets that often form part of a manufacturer’s 
own specification which are quantifiable by the 
crushing strength (CS) and the friability (F) of 
the tablets. The CS provides a measure of 
tablet strength while F is a measure of tablet 
weakness
15,16
. Both parameters indicate the 
ability of tablets to withstand fracture and 
abrasion during production and subsequent 
use
15,17
. The Pharmacopoeial requirements
15
 
for the crushing strength is largely dependent 
on the intended use of the tablet, while for 
friability, conventional compressed tablets that 
lose less than 1%w/w of their mass during the 
friability test are generally considered 
acceptable
15,16,18
. Only tablets prepared using 
Avicel
®
 as directly compressible excipient 
passed the test for friability by losing less that 
1% of their weight. This indicates that lactose 
and Emcompress
®
 at the concentration used 
appears not suitable for the production of A. 
boonei tablets since the tablets possessed 
high friability values. Tablets prepared by wet 
granulation using all the binders on the other 
hand, showed acceptable CS and F values at 
the concentrations employed, indicating the 
suitability of wet granulation method for the 
production of A. boonei tablets. Furthermore, 
there were statistically significant (p<0.01) 
differences in the CSFR values of A. boonei 
tablets prepared by both methods. The CSFR 
values of the tablets prepared wet granulation 
were significantly (p<0.01) higher than those 
prepared by direct compression except for 
formulation containing Avicel®. Thus, the 
mechanical properties of the tablets were 
affected by the type and concentration of 
diluent/binder employed. The differences 
depended on the type and concentration of 
excipient and binder employed in the 





All formulations of A. boonei tablets complied 
with the official requirement on disintegration 
(i.e. disintegration within 15 minutes), with the 
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disintegration time greater than 60 minutes. 
Statistical analysis showed that tablets 
prepared using 90%w/w Avicel
®
 as excipient 
had significantly (p<0.001) higher 
disintegration and dissolution times than those 
prepared using the other excipients. The 
dissolution times of the tablets prepared by 
wet granulation also varied and depended on 
the type and concentration of the binding 
agent employed. Tablet prepared by wet 
granulation did not meet the official 
requirement on dissolution for uncoated 
tablets (i.e release of 75%w/w of the active 
drug within 45min)
15
 except for tablets 
prepared using corn starch as binding agent. 
There were generally significant (p<0.05) 
differences in the dissolution times of tablets 
prepared by both methods. Although A. 
boonei extract alone formed tablets with high 
bond strength, the tablets however did not 
meet the requirement on dissolution. This may 
be due to the absence of other excipient in the 
formulation. The results indicate the 
importance of the inclusion of excipients such 
as disintegrant in the formulation of A. boonei 
tablets. 
 
It is noteworthy that A. boonei tablets 
containing Avicel
®
 which produced tablets of 
acceptable mechanical properties, however 
failed to comply with the requirements on 
dissolution and disintegration. On the other 
hand, only tablets containing corn starch as 
binding agent, used in wet granulation, fulfilled 
the pharmacopoeial requirements on 
mechanical and drug release properties. Wet 
granulation appears to produce tablets of 
acceptable mechanical and drug release 
properties than those prepared by direct 
compression. Thus, the methods of 
preparation of the A. boonei tablets need to be 
carefully selected to ensure the production of 
tablets with adequate bond strength to 
withstand the rigors of handling and at the 
same time release the active compound (s) for 
biological action. Furthermore, the type and 
concentration of excipient and binder 
employed in the formulation of A. boonei 
tablets need to be carefully chosen to enable 
the production of suitable tablets. 
   
CONCLUSION 
The result obtained shows that the methods of 
preparation of the A. boonei tablets need to be 
carefully selected to ensure the production of 
tablets with adequate bond strength to 
withstand the rigors of handling and at the 




















Figure 1: The release profile of A. boonei tablets containing the (●) extract alone, (■) Avicel
® 
(1:4) as 
direct compression excipient and (▲) 1%w/w cornstarch as binder compressed at 5KN (Error bars = 
mean±SD)  
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biological action. Furthermore, the type and 
concentration of excipient and binder 
employed in the formulation of A. boonei 
tablets need to be carefully chosen to enable 
the production of suitable tablets. 
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